FDA Approves Foundation Medicine’s FoundationOne Liquid CDx, a Comprehensive Pan-Tumor Liquid Biopsy Test

Washington, DC, August 28, 2020 – This week, the U.S. Food and Drug Administration (FDA) approved Foundation Medicine, Inc.’s comprehensive pan-tumor liquid biopsy test called FoundationOne Liquid CDx. This test analyzes more than 300 genes and genomic signatures to help inform treatment decisions for all solid tumor cancers including melanoma. This will become commercially available starting today, Friday, August 28, 2020 and is covered across all solid tumors for eligible Medicare and Medicare Advantage beneficiaries in accordance with the Centers for Medicare and Medicaid Services (CMS) National Coverage Decision Memo criteria, according to Foundation Medicine. To learn more about this new diagnostic testing, follow this link to Foundation Medicine’s press release.